ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2024
The Association Between Antioxidant Enzyme Polymorphisms with Type 2 Diabetes Mellitus in Jazan Province.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by persistent hyperglycemia, which results in initiates oxidative stress and disrupts various cellular pathways. In this study, we examined the relationship between polymorphisms in antioxidant enzymes, specifically glutathione peroxidase 1 (GPx1) and catalase (CAT), and the susceptibility to T2DM in a Saudi population from the Jazan Province. Methods: A total of 419 participants were evaluated, including 247 T2DM patients and 172 controls. They were genotyped for the GPx1 Pro198Leu and CAT-262C/T polymorphisms by a PCR-based method. Results: The results indicated that individuals with the CAT T/T genotype had a 60% lower likelihood of developing T2DM compared with those harboring the C/C genotype (uOD 0.4; 95% CI 0.2-0.8, p = 0.04); however, no significant association was observed between the GPx1 polymorphism and T2DM. Discussion: The results suggest that CAT polymorphism may confer a protective effect against T2DM, whereas the GPx1 polymorphism appears not to be a determinant of T2DM susceptibility in this population. Further studies including larger and more diverse cohorts are necessary to validate these results and elucidate the underlying mechanisms. Understanding the genetic factors that contribute to T2DM is essential for developing targeted preventive and therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.